36. Price DE, Cooksey G, Jehu D, et al. The management of impotence in diabetic men by vacuum tumescence therapy. *Diabetic Med* 1991; 8: 964-7
37. Ryder REJ, Close CF, Moriarty KT, et al. Impotence in diabetes: aetiology, implication for treatment and preferred vacuum device. *Diabetic Med* 1992; 9: 893-8
38. Derouet H, Zehl U. Treatment of erectile dysfunction with vacuum pumps. *Urologe A* 1993; 32: 312-5
39. Wespes E, Schulman CC. Venous leakage: surgical treatment of a curable cause of impotence. *J Urol* 1985; 133: 796-8
40. Wilson SK, Wahman GE, Lange JL. Eleven years of experience with the inflatable penile prosthesis. *J Urol* 1988; 139: 951-2
41. McCulloch DK, Hosking DJ, Tobert A. A pragmatic approach to sexual dysfunction in diabetic men: psychosexual counselling. *Diabetic Med* 1986; 3: 485-9
42. Alexander WD. The diabetes physician and an assessment and treatment programme for male erectile impotence. *Diabetic Med* 1990; 7: 540-3

Correspondence and reprints: Dr P.G. Wiles, Diabetes Centre, North Manchester Healthcare NHS Trust, Crumpsall, Manchester M8 6RB, England.

Errata

Vol. 49, No. 1, page 24: The fifth sentence of section 4.2.1 should read, 'Exactly 25% (8) of these individuals each die 3, 9, 15 and 21 months after the onset of AIDS'.

[Hoover DR. *The effects of long term zidovudine therapy and Pneumocystis carinii prophylaxis on HIV disease: a review of the literature.* *Drugs* 1995 Jan; 49 (1): 20-36]

Vol. 49, No. 2, page 299: In figure 1, the structures of doxazosin, prazosin and terazosin should be as follows:

Doxazosin

Prazosin

Terazosin

[Fulton B, Wagstaff AJ, Sorkin EM. *Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.* *Drugs* 1995 Feb; 49 (2): 295-320]